Background: Pharmacogenetics is a scientific discipline that examines the genetic basis for individual variations in response to therapeutics. Pharmacogenetics promises to develop individualized medicines tailored to patients' genotypes. However, identifying and genotyping a vast number of genetic polymorphisms in large populations also pose a great challenge. Approach: This article reviews the recent technology development in mutation detection and genotyping with a focus on genotyping of single nucleotide polymorphisms (SNPs). Content: Novel mutations/polymorphisms are commonly identified by conformation-based mutation screening and direct high-throughput heterozygote sequencing. With a large amount of public sequence information available, in silico SNP mapping has also emerged as a cost-efficient way for new polymorphism identification. Gel electrophoresis-based genotyping methods for known polymorphisms include PCR coupled with restriction fragment length polymorphism analysis, multiplex PCR, oligonucleotide ligation assay, and minisequencing. Fluorescent dye-based genotyping technologies are emerging as high-throughput genotyping platforms, including oligonucleotide ligation assay, pyrosequencing, single-base extension with fluorescence detection, homogeneous solution hybridization such as TaqMan ® , and molecular beacon genotyping. Rolling circle amplification and Invader TM assays are able to genotype directly from genomic DNA without PCR amplification. DNA chip-based microarray and mass spectrometry genotyping technologies are the latest development in the genotyping arena.
age analysis, i.e., studies of the tendency of certain genes to be inherited together in families.
Although microsatellites have been used in linkage analysis in the past, it is becoming increasingly popular to use SNP markers because they are the most frequent DNA sequence variations found in the human genome. Genotyping large number of SNPs in linkage and association studies will shed new light to the understanding of complex disease traits, including many common human diseases and drug responses (3 ) . SNP genotyping is also easier to automate because SNPs can be screened in a digital format by analyzing the presence or absence of a sequence. The SNP Consortium was created in 1999 by pharmaceutical companies and the Wellcome Trust to develop a catalog of 300 000 SNPs for public usage. It is projected that the consortium will generate 1 000 000 SNPs by the end of the first quarter of year 2001 (Arthur Holden, personal communication). The high-density SNP map will allow researchers to expand their capabilities for identification of critical diseases and drug response genes in nonfamilial studies.
With the completion of the human genome map and the SNP map, genotyping SNPs in large-scale pharmacogenetic studies will be an integrated part of the drug discovery and development process. Advanced technologies to identify genetic polymorphisms rapidly, accurately, and economically are becoming a priority in the implementation of pharmacogenetics to drug development, clinical trials, and clinical monitoring for drug efficacy and toxicity. Pharmacogenetics will have a major impact on the healthcare and medical practice by enabling selection of the right drugs for the right patients at the right doses through genetics-based diagnostic tests (3 ) . In this article, I review the current technological progress on mutation detection and genotyping with an emphasis on high-throughput technologies for SNP genotyping.
Identification of New Polymorphisms
A variety of techniques are available for new mutation/ polymorphism identification. One commonly used strategy for SNP screening is to amplify genes of interest by PCR, scan the PCR products for the presence of DNA variants by confirmation-based mutation scanning methods, and then sequence positive PCR products. The development of new-generation DNA sequencers also allows direct heterozygote sequencing frequently used in SNP identification. With a vast amount of human expressed sequence tags (ESTs) and genomic clones in the public domain, computer-based sequence alignment and clustering also provide a rich source for SNP identification.
conformation-based mutation scanning
Single-strand conformation polymorphism analysis is one of the most widely used methods for mutation detection. In single-strand conformation polymorphism, DNA regions with potential polymorphisms are first amplified by PCR. Single-stranded DNAs are then generated by denaturation of the PCR products and separated on a nondenaturing polyacrylamide gel. A fragment with a single base modification generally forms a different conformer and migrates differently when compared with wild-type DNA ( Fig. 1) (4, 5 ) . The sensitivity can be increased to nearly 100% by coupling with either restriction enzyme fingerprinting (6 ) or dideoxy-sequencing fingerprinting (7 ) .
Other alternative conformation-based mutation screening methods include conformation-sensitive gel electrophoresis (8 ) , chemical or enzymatic mismatch cleavage detection (9 -11 ) , denaturing gradient gel electrophoresis (12 ) , and denaturing HPLC (13 ) . The underlying principle of these methods is that the melting characteristics of double-stranded DNA are largely defined by its sequence. Therefore, a single-base mismatch can produce conformation changes in the double helix that cause the differential Single-stranded DNAs are generated by denaturation of the PCR products and separated on a nondenaturing polyacrylamide gel. A fragment with a single-base modification generally forms a different conformer and migrates differently when compared with wild-type DNA. migration of homoduplexes and heteroduplexes containing base mismatches during gel electrophoresis. Conformation-sensitive gel electrophoresis has been developed to distinguish homoduplexes from heteroduplexes containing a single mismatched base pair by polyacrylamide gel electrophoresis in a mildly denaturing solvent system. This method has been shown to be highly sensitive for identifying mutations in areas of highly repetitive and GC-rich sequences (14 ) .
Mismatch cleavage detection takes advantage of the fact that mismatched bases are sensitive to cleavage by enzymes or chemicals. After PCR amplification, the wildtype and variant products are subjected to denaturation/ renaturation to create heteroduplex molecules. After incubation with resolvases or chemicals, the products are resolved electrophoretically side by side to score for the presence of mismatch-cleaved molecules (9 -11 ) .
In denaturing gradient gel electrophoresis, genomic DNA is PCR amplified and the products are resolved in a polyacrylamide gel with an increasing denaturing gradient of formamide and urea under careful temperature control. Heteroduplex DNA fragments with a single mismatched base pair are revealed by migrational differences from homoduplexes. The advantages of this method are its high accuracy and relatively low costs. The disadvantages are low throughput and difficulty of optimization (12 ) .
Denaturing HPLC detects polymorphisms by analyzing the DNA mobility of different heteroduplexes using chromatography in a slightly denaturing condition. The WAVE ® DNA analysis system is a commercialized method from Transgenomic, Inc. (San Jose, CA) that uses temperature-modulated heteroduplex analysis (15 ) . The variant sample first is hybridized with wild-type DNA to form a mixture of homo-and heteroduplexes. The heteroduplexes can be separated from the homoduplexes by column chromatography at a temperature that partially denatures the mismatched DNA. The advantage of using the WAVE system is that multiple samples could be pooled into a single reaction for variant detection. Therefore, it can substantially increase the throughput compared with DNA sequencing.
direct dna sequencing
Conformation-based mutation screening tools are a costeffective way to detect novel polymorphisms. Once the potential regions have been confirmed to contain putative polymorphisms, these regions can be sequenced to locate the final polymorphic sites (Fig. 2 ). With the improvement of computer software and detection systems, fluorescent DNA sequencing has become fully automated for the DNA sequencing process. The SNP Consortium has been identifying SNPs using this technology by sequencing and comparing multiple individuals' sequences. The 3700 genetic analyzer (Applied Biosystems, Foster City, CA) and MegaBACE TM (Amersham Pharmacia Biotech, Uppsala, Sweden) systems are fully automated sequencers that are emerging as vital technology platforms for largescale DNA sequencing projects.
in silico snp mapping
The Human Genome Project has produced large amounts of sequence data in the public databases. These EST and genomic DNA sequences provide a rich source for in silico identification of SNPs. Through fragment clustering and multiple alignment of the sequences from redundant EST and bacterial artificial chromosome clones, potential SNPs can be identified without the initial effort to sequence multiple individuals. A computer SNP screening algorithm called POLBAYES was developed and is available at no cost for nonprofit usage (16 ) (instructions at http://genome.wustl.edu/gsc/polybayes). By calculating the probability scores, putative SNPs can be identified. These putative SNPs can be confirmed by resequencing in multiple individuals. Obviously, this is a fast and cost-efficient way to identify new SNPs.
Gel-based Genotyping Methods for Detecting Known
Polymorphisms pcr-restriction fragment length polymorphism analysis Commonly used methods include gel electrophoresisbased techniques such as PCR coupled with restriction fragment length polymorphism analysis. Specific regions of DNA sequences can be PCR amplified. The PCR products then are digested with appropriate restriction enzymes and visualized by staining the gel after electrophoresis. If the genetic polymorphism produces a gain or loss of the restriction site, a different restriction digestion pattern can be recognized (17 ) . A major limitation of the PCR-restriction fragment length polymorphism method is the requirement that the polymorphisms alter a restriction enzyme cutting site (17 ) .
oligonucleotide ligation assay genotyping
The oligonucleotide ligation assay (OLA) relies on hybridization with specific oligonucleotide probes that can effectively discriminate between the wild-type and variant sequences. Three oligonucleotides are used in OLA: two allele-specific oligonucleotide probes (one specific for the wild-type allele and the other specific for the mutant allele) plus a fluorescent common probe. The 3Ј ends of the allele-specific probes are immediately adjacent to the 5Ј end of the common probe. The gene fragment containing the polymorphic site is amplified by PCR and incubated with the probes. In the presence of thermally stable DNA ligase, ligation of the fluorescent-labeled probe to the allele-specific probe(s) occurs only when there is a perfect match between the variant or the wild-type probe and the PCR product template. These ligation products are then separated by electrophoresis, which permits the recognition of the wild-type genotypes, the variants, the heterozygotes, and the unligated probes ( Fig. 3 ). By varying the combinations of color dyes and probe lengths, multiple mutations can be detected in a single reaction (18 ) . This method can be used to genotype a large panel of informative biallelic markers. The hybridization of allelespecific oligonucleotides is dependent on both the variant and the surrounding sequences. Highly GC-rich DNA regions make the allele-specific ligation step in OLA difficult to optimize and multiplex.
minisequencing Similar to regular DNA sequencing, minisequencing is an efficient way to detect SNPs through the addition of specific nucleotides to a single primer (19 ) . Several SNP markers can be analyzed in parallel by the use of locusspecific primers and analyzing the allele-specific incorporation of labeled nucleotides (20 ) . To increase the throughput, new sets of reaction products can be loaded onto the same gel.
Overall, gel-based genotyping assays are relatively straightforward and are useful when dealing with a small number of samples. The methods are labor-intensive and require experienced and skilled technical staff for final analysis. Although gel-based genotyping methods are still widely used in many laboratories, they are difficult to apply to high-throughput genotyping in large-scale pharmacogenetic studies.
Non-Gel-based High-Throughput Genotyping Technologies
Non-gel-based high-throughput genotyping technologies are rapidly evolving as the dominant genotyping platforms for large-scale pharmacogenetic studies. Current genotyping methods include fluorescent dye-based highthroughput genotyping procedures such as homogeneous solution hybridization, allele-specific OLA and minisequencing. High-density chip array and mass spectrometry (MS) similarly have been used for genotyping both known and unknown polymorphisms.
homogeneous solution hybridization using fluorescence resonance energy transfer detection Two allele-specific oligonucleotide probes (one specific for the wild-type allele and the other specific for the variant allele) and a fluorescent common probe are used in each assay. The 3Ј ends of the allele-specific probes are immediately adjacent to the 5Ј end of the common probe. In the presence of thermally stable DNA ligase, ligation of the fluorescently labeled probe to the allele-specific probe(s) occurs only when there is a perfect match between the variant or the wild-type probe and the PCR product template. These ligation products are then separated by electrophoresis, which permits the recognition of the wild-type genotypes, the variants, the heterozygotes, and the unligated probes. and the emission spectrum of one fluorophore overlaps the excitation spectrum of the other fluorophore (21 ) . Commonly used FRET-based technologies include the TaqMan ® assay and molecular beacons. The Invader TM assay is a new technology enabling genotyping SNPs without PCR.
TaqMan genotyping. The TaqMan Allelic Discrimination assay uses the 5Ј nuclease activity of Taq polymerase to detect a fluorescent reporter signal generated during or after PCR reactions (22 ) . For SNP genotyping, one pair of TaqMan probes and one pair of PCR primers are used. The assay uses two TaqMan probes that differ at the polymorphic site, with one probe complementary to the wild-type allele and the other to the variant allele. A 5Ј reporter dye and a 3Ј quencher dye are covalently linked to the wild-type or variant allele probes. When the probes are intact, fluorescence is quenched because of the physical proximity of the reporter and quencher dyes. During the PCR annealing step, the TaqMan probes hybridize to the targeted polymorphic site. During the PCR extension phase, the 5Ј reporter dye is cleaved by the 5Ј nuclease activity of the Taq polymerase, leading to an increase in the characteristic fluorescence of the reporter dye. Specific genotyping is determined by measuring the signal intensity of the two different reporter dyes after the PCR reaction (Fig. 4 ). In addition to detecting SNPs (23 ), small gene deletions and insertions can also be identified by this method (24 ) . TaqMan genotyping instrumentation and reagents are supported by Applied Biosystems.
Molecular beacons. Molecular beacons are oligonucleotide probes that have two complementary DNA sequences flanking the target DNA sequence and a donor-acceptor dye pair at opposite ends of each probe. When not hybridized to the target, the probe adopts a hairpin-loop conformation with the reporter and quencher dyes close together, and therefore, no donor fluorescence is generated. When hybridized to the right target sequence, the two dyes are separated and the fluorescence is increased dramatically (25 ) . Mismatched probe-target hybrids dissociate at substantially lower temperature than exactly complementary hybrids. This thermal instability of mismatched hybrids increases the specificity of molecular beacons. For SNP genotyping, two molecular beacons with exact sequence matches to the wild-type and variant alleles are used in the same PCR reaction. These two molecular beacons are labeled with different fluorophores that emit fluorescent light at distinct optical wavelengths. The use of two differentially labeled molecular beacons in the same PCR reaction allows simultaneous determination of three possible allelic combinations. The molecular beacon technology has been commercialized by Stratagene (La Jolla, CA).
Invader assay. The Invader assay (Third Wave Technologies, Inc., Madison, WI) is an attractive FRET-based genotyping method with the potential to genotype SNPs without PCR amplification. Two oligonucleotides, a wildtype or variant signal probe plus an upstream Invader Two TaqMan probes targeted at the polymorphic site are labeled with different reporter dyes (R1 and R2) and a common quencher dye (Q). Only the perfectly hybridized probe will be cleaved by the Taq polymerase during the extension phase of the PCR reaction. A mismatched probe will not be recognized by the Taq polymerase. At the end of the genotyping reaction, the PCR product is analyzed for changes in fluorescence intensities of the reporter dyes R1 and R2. The ratio of two reporter dyes will determine the genotype of the sample.
probe, are used in each reaction. These probes hybridize in tandem to a specific region of genomic DNA. When the 3Ј end of an upstream oligonucleotide overlaps the hybridization site of the 5Ј end of a downstream oligonucleotide probe by at least one base pair, the structure will be recognized and cleaved by Cleavase ® enzymes, a class of naturally occurring and engineered enzymes (26, 27 ) . A single-nucleotide mismatch immediately upstream of the cleavage site renders the confirmation unrecognizable by Cleavase. Invader assays are conducted isothermally, and a linear increase in signal over time will be produced ( Fig.  5 ). Each cleavage product then serves as an Invader oligonucleotide in a secondary reaction, where it directs the cleavage of a combined labeled FRET probe-template construct. This secondary oligonucleotide probe is 5Ј end-labeled with the donor fluorophore, which is quenched by an internal acceptor dye. When the DNA is cleaved, the donor and acceptor dyes are no longer in close proximity, the quenching is abolished, and fluorescence is generated. Assays are read with a fluorescence plate reader, and genotypes are assigned after determination of the net wild-type/variant signal ratio for each sample (26, 28 ) .
FRET-based genotyping approaches are fast and often can be monitored in real time. In addition, these assays can use standard microtiter plates in 96-to 1536-well formats. The ability to automate data handling further enhances accuracy by eliminating operator bias. These assays are robust for large-scale characterization of the same genetic polymorphism. Both TaqMan and molecular beacon assays require dual-labeled probes and PCR reactions, which are likely more expensive than the Invader technology.
allele-specific ligation
Dye-labeled oligonucleotide ligation. Dye-labeled oligonucleotide ligation combines PCR-OLA with FRET detection in a one-step homogeneous assay. The PCR primers used in the assay are designed to have high melting temperatures. The three dye-labeled ligation probes for each SNP are designed to have low melting temperatures. A 5Ј donor dye-labeled common probe terminates one base immedi-ately upstream from the polymorphic site. Two allelespecific 5Ј-phosphorylated, 3Ј-acceptor dye-labeled probes have polymorphic nucleotides at the 5Ј end. A thermostable DNA polymerase with no 5Ј nuclease activity (AmpliTaq FS) and a thermostable DNA ligase are used. The first stage of PCR reaction is kept at high temperature, and the ligation probes are unable to anneal. After sufficient PCR products are generated, the second stage of the reaction, with a low annealing temperature, allows ligation to occur. By analyzing the fluorescence signals of all the dyes, individual genotypes can be determined directly after one reaction using real-time PCR or by end-point signal analysis using a fluorescent plate reader (29 ) .
Rolling circle amplification (RCA). Like the Invader assay, RCA is also sensitive enough to work directly from genomic DNA (30, 31 ) . For each SNP, two allele-specific probes are designed to discriminate between the two alleles. Each probe consists of a single oligonucleotide 80 -90 bases in length. The 5Ј end of the probe is phosphorylated and bears a sequence of 20 nucleotides that is complementary and, therefore, will hybridize to the region immediately 5Ј of the SNP. The 3Ј end of the probe contains 10 -20 nucleotides complementary to the region immediately 3Ј of the SNP. Both allele-specific probes are identical with the exception of the 3Ј base, which is varied to complement the two alleles at the polymorphic site. The two probes contain two different generic backbone sequences. A generic backbone that encodes binding sites for two RCA amplification primers is sandwiched between the allele-specific probe arms. The first stage of the assay involves ligation of the probes to the target DNA by allelic discrimination. After denaturation of the target genomic DNA, both allele-specific probes are then added to the denatured DNA. A stable hybrid is formed only if the 3Ј base of the probe is perfectly matched to the polymorphic nucleotide present in the target. Complete hybridization aligns the two ends of the probe together on the target DNA and circularizes the probe by a thermostable ligase. Amplification of a circularized probe by RCA requires the first primer to hybridize to its complementary region on the probe backbone. In the presence of The Invader assay involves the hybridization of two sequence-specific oligonucleotides, Invader and signal probes. The signal probe contains a portion perfectly matched to the target DNA and a fluorescently labeled Flap. The overlapping hybridization of the Invader probe and signal probe to the target DNA generates a specific structure. When the Invader probe invades at least one nucleotide into the downstream duplex, this unique structure is recognized and cleaved by the Cleavase. The cleaved signal probe dissociates, and a new signal probe anneals and is subsequently cleaved. The process repeats multiple times, producing linear amplification of the fluorescent signal. When there is no perfect match between the Invader probe and the DNA template, the invasion is lost and there is no fluorescent signal generated. a strand-displacing DNA polymerase, the primer is extended, eventually displacing itself at its 5Ј end once one complete revolution of the circularized probe is made. Continued polymerization and displacement generates a single-stranded, concatameric DNA copy of the original probe. The isothermal process is amenable to automation, and the generic amplification primers keep reagent costs low. A FRET-based RCA assay called SNIPER TM has been developed and is in the initial stage of commercialization by Amersham Pharmacia Biotech.
allele-specific nucleotide incorporation
Pyrosequencing. Pyrosequencing detects de novo incorporation of nucleotides based on the specific template. The incorporation process releases a pyrophosphate, which is converted to ATP in the presence of adenosine 5Ј-phosphosulfate, which in turn stimulates luciferase. The light production in the luciferase-catalyzed reaction is detected by a charge couple device camera. The height of each peak correlates to the light signal and is proportional to the number of nucleotides incorporated. ATP and unincorporated dNTPs are continuously degraded by apyrase. The light is switched off, and the next dNTP is added. As the process continues, the complementary DNA strand is built up and the nucleotide sequence is determined from the signal peak in the pyrogram. Current instrumentation, sold by Pyrosequencing AB (Uppsala, Sweden), can detect 500 SNPs/h post-PCR in a 96-well format (32 ) .
Single-base extension with fluorescence detection. A popular SNP genotyping method is the template-directed dye terminator incorporation assay with fluorescent polarization (FP) detection. FP is based on the principle that a small molecule tumbles rapidly in solution. If planepolarized light is shone on fluorescent dye labels, the molecules tumble rapidly, and the emission is depolarized. If the viscosity and temperature are constant, FP is directly proportional to the molecular volume, which is directly proportional to the molecular weight (33 ) . The sequencing primer is immediately upstream from the polymorphic site. When incubated in the presence of dideoxynucleotide triphosphates labeled with different fluorophores, the allele-specific dye-labeled dideoxynucleotide triphosphate is linked to the primer in the presence of DNA polymerase and target DNA. The genotype of the target DNA molecule can be determined simply by exciting the fluorescent dye in the reaction and determining the change in FP (33 ) . LJL Biosystem (Sunnyvale, CA) has developed a high-throughput genotyping system using this technology.
dna microarray genotyping
The DNA microarray is a hybridization-based genotyping technique that offers simultaneous analysis of many polymorphisms. High-density microarrays are created by attaching hundreds of thousands of oligonucleotides to a solid silicon surface in an ordered array. The DNA sample of interest is PCR amplified to incorporate fluorescently labeled nucleotides and then hybridized to the array. Each oligonucleotide in the high-density array acts as an allelespecific probe. Perfectly matched sequences hybridize more efficiently to their corresponding oligomers on the array and, therefore, give stronger fluorescent signals over mismatched probe-target combinations. The hybridization signals are quantified by high-resolution fluorescent scanning and analyzed by computer software. DNA alterations such as heterozygous base-pair polymorphisms or mutations, insertions, and deletions can be identified (34, 35 ) .
Sequencing by hybridization can be an efficient method to monitor a large number of SNPs. It is possible to array a set of short oligonucleotides covering the entire DNA fragment on a DNA chip. Because the precise sequence of the oligonucleotide at each location on the chip is known, the pattern of hybridization can be determined using fluorescently labeled DNA probes. The advantage of this method is that a large DNA fragment or a large collection of small PCR products can be scanned in one hybridization. More than 100 such arrays have been used for high-throughput screening of SNPs covering more than 2 Mb of genomic DNA (36 ) and thousands of SNPs have been screened rapidly by use of chip-based resequencing (37 ) .
Once a high-density SNP map is generated, application of microarray technology to simultaneously monitor tens of thousands of genetic variations will provide major advantages for genome-wide screening. The application of these chip-based genotyping technologies is currently under development and evaluation in several companies, including Affymetrix (Santa Clara, CA), Protogene (Menlo Park, CA), Genometrix (The Woodlands, TX), and Motorola BioChip Systems (Northbrook, IL). Several arrays have been generated to detect variants in the HIV genome, p53, human mitochondria mutations, and human cytochrome p450 polymorphisms. The current limitation is that homozygous variants are readily detected but heterozygous may be missed, and deletions and insertions will not be specifically recognized. Although expensive now, the cost of chips as a major screening platform in pharmacogenetics will likely be reduced with analyses of hundreds of thousands of patients. Genometrix has developed a low-cost, medium-density array format using a multiplex capillary printer and high-speed robotics. Each array contains up to 256 elements, and 96 arrays can be processed in parallel on a single plate. For SNP genotyping, wild-type and variant-specific probes are printed side by side in each array. Target sequences containing the polymorphisms of interest are derived by multiplex PCR reaction from genomic DNA sequences. By analyzing the fluorescent signals after hybridization, multiple SNPs can be genotyped in a single array ( Fig. 6) (38 ) . ms Large molecules can be identified by MS through electrospray or matrix-assisted laser desorption ionization and ion-trap or time-of-flight detectors. MS yields precise information on the molecular mass of the DNA fragments. The procedure can be fully automated, and both DNA strands can be analyzed in parallel (39 ) . Unlike the fluorescent genotyping methods described above, MS offers specificity and accuracy without requiring specially labeled probes or primers. One disadvantage of this technique is that it requires purified samples free of ions and other impurities, thus increasing the technical time and sample-processing costs. A chip-based genotyping method using MS has been described (40 ) . PCR can be performed in 1-L reactions directly in the chip wells in parallel. The PCR product can be detected in situ using matrix-assisted laser desorption ionization MS. This miniaturization technique has the potential for high-throughput, low-cost genotyping. The MassARRAY instrumentation for SNP genotyping has been commercialized by Sequenom, Inc. (La Jolla, CA).
Conclusions and Perspectives
A major challenge for large-scale pharmacogenetic studies is to compare hundreds of thousands of polymorphisms among numerous individuals. Thus, the success of pharmacogenetics depends on user-friendly technologies that can detect polymorphisms rapidly, accurately, and cost effectively on a large scale. Each of the methods discussed above has been demonstrated to work in a variety of settings, but each method has its limitations. Of all the options available, FRET-based and chip-based genotyping technologies will most likely evolve as the ultra-high-throughput detection systems to meet the re-quirements of pharmacogenetics. For DNA microarrays, a better approach is to fabricate a generic array containing tag sequences close to the polymorphic sites. Genotyping can be conducted by use of fluorescently labeled singlebase extension reactions or OLAs. For discovery work in pharmacogenetics, large numbers of SNPs can be genotyped using high-density arrays. Once the association has been established, a limited number of SNPs probably will be included in routine clinical trials or clinical practice using medium-density array genotyping. With advanced genotyping technologies, pharmacogenetics will revolutionize our concepts of modern medicine by allowing physicians to prescribe the most effective and safest drug based on a patient's genetic blueprint.
